Recalls of generic Zantac believed to be contaminated by a carcinogen continue to flood in. Two other firms have declared recalls of ranitidine heartburn meds in 150 mg and 300 mg doses. The news arrived even as the degree of the drug returns increased with Mylan’s impromptu recall of three lots of nizatidine capsules last week because the API in them also held dangerous levels of NDMA.
Shortly after the Federal officials announced the voluntary recalls of some pharmacies over NDMA, a drug filled with a potential human carcinogen, many other pharmacies have recalled the common variety of heartburn drug Zantac, called ranitidine, from shelves.
Additional generic editions of Zantac are being taken down from pharmacy shelves after officials detected low levels of a possible carcinogens in the heartburn medication.
The Stryker Tritanium Acetabular Shell, which restores the human hip socket, is built from a titanium alloy covered with a unique kind of porous foam. The foam enables bone cells to bind with it and grow, thereby increasing joint stability. However, a 2018 report in the journal Arthroplasty Today by doctors at NYU Langone Orthopedic Hospitals described five hip implant failures related to Stryker’s Tritanium cups between 2011 and 2016.
According to the National Financial Capability Study, the majority of Americans — and especially millennials, minorities, and single women — have lost confidence and a feeling of stability when it comes to their personal finances. Remarkably, these feelings have arisen in spite of the fact that the economy has been steadily improving over the same period of time.
According to FINRA, while there is no airtight definition of a high-risk (yet), the regulatory body deploys a set of criteria to help identify these individuals and ratchet up the oversight on them. However you can use these criteria yourself to evaluate your own or a potential FA for excessively risky behavior.
Last month, the Financial Industry Regulatory Authority (FINRA) published its Regulatory and Examinations Priorities Letter. While the express purpose of this letter is to advise stock brokers and compliance officers about the focus of the accreditation exams many of them will be taking in 2015, the letter also indirectly puts investors and securities professionals on notice.
2332 South Broad Street
Philadelphia PA 19145
p: 215 462 3330 / f: 215-567-1941
